HALEON PLC
LSE:HLN

Watchlist Manager
HALEON PLC Logo
HALEON PLC
LSE:HLN
Watchlist
Price: 380.3 GBX 2.12% Market Closed
Market Cap: 34.4B GBX
Have any thoughts about
HALEON PLC?
Write Note

HALEON PLC
Cash & Cash Equivalents

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

HALEON PLC
Cash & Cash Equivalents Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash & Cash Equivalents CAGR 3Y CAGR 5Y CAGR 10Y
HALEON PLC
LSE:HLN
Cash & Cash Equivalents
ÂŁ1B
CAGR 3-Years
55%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Unilever PLC
LSE:ULVR
Cash & Cash Equivalents
€1.3B
CAGR 3-Years
-32%
CAGR 5-Years
-20%
CAGR 10-Years
-9%
PZ Cussons PLC
LSE:PZC
Cash & Cash Equivalents
ÂŁ49.4m
CAGR 3-Years
-15%
CAGR 5-Years
0%
CAGR 10-Years
-3%
Science in Sport PLC
LSE:SIS
Cash & Cash Equivalents
ÂŁ1.5m
CAGR 3-Years
-43%
CAGR 5-Years
-21%
CAGR 10-Years
N/A
Warpaint London PLC
LSE:W7L
Cash & Cash Equivalents
ÂŁ5.5m
CAGR 3-Years
-6%
CAGR 5-Years
9%
CAGR 10-Years
N/A
Venture Life Group PLC
LSE:VLG
Cash & Cash Equivalents
ÂŁ5.6m
CAGR 3-Years
-11%
CAGR 5-Years
-13%
CAGR 10-Years
27%
No Stocks Found

HALEON PLC
Glance View

Market Cap
34.7B GBX
Industry
Consumer products

Haleon PLC emerged as a significant player in the global consumer health market when it was spun off from GlaxoSmithKline in July 2022. As a standalone entity, Haleon focuses on delivering everyday health products that enhance personal well-being, relying on a portfolio brimming with trusted brands like Sensodyne, Panadol, and Voltaren. With an impressive presence in over 100 countries, the company capitalizes on the growing consumer shift towards preventative healthcare and wellness, offering a range of over-the-counter medications, oral health products, and vitamins. This strategic approach positions Haleon not only as a trusted name but also as a vital contributor to the ongoing trend of self-care, making it an intriguing option for long-term investors seeking growth in resilient sectors. As Haleon charts its path forward, the company emphasizes sustainable growth and innovation, seeking to resonate with health-conscious consumers amid an increasingly competitive landscape. By investing in research and development, Haleon aims to expand its product offerings and enhance its market position. The company's focus on operational efficiency, coupled with strategic partnerships and an agile supply chain, reflects its commitment to driving profitability and shareholder value. With a strong foundation rooted in consumer trust and a forward-looking vision, Haleon PLC stands ready to navigate the evolving health landscape, presenting an appealing narrative for investors drawn to enterprises poised for sustainable success.

HLN Intrinsic Value
336.95 GBX
Overvaluation 11%
Intrinsic Value
Price

See Also

What is HALEON PLC's Cash & Cash Equivalents?
Cash & Cash Equivalents
1B GBP

Based on the financial report for Dec 31, 2023, HALEON PLC's Cash & Cash Equivalents amounts to 1B GBP.

What is HALEON PLC's Cash & Cash Equivalents growth rate?
Cash & Cash Equivalents CAGR 3Y
55%

Over the last year, the Cash & Cash Equivalents growth was 72%. The average annual Cash & Cash Equivalents growth rates for HALEON PLC have been 55% over the past three years .

Back to Top